A 2026 Medicare target-trial emulation found continued levetiracetam after acute ischemic stroke was associated with 53 vs. 62 deaths per 1,000 over 90 days, a risk difference of −9 deaths per 1,000 favoring continuation. Research Highlights Survival signal: continued levetiracetam after an initial month of post-stroke use was linked to 53 deaths per 1,000 vs. …
A 2026 medRxiv study of 30 adults with drug-resistant focal epilepsy found that dynamic FDG-PET had higher model-adjusted signal quality than static PET in most brain regions, including >80% posterior probability of superiority in 29 of 36 regions. Research Highlights Dynamic PET beat static PET: interictal dynamic FDG-PET showed higher signal quality than static PET …
A 2026 first-in-human medRxiv preprint reported that closed-loop subgaleal intersectional short-pulse stimulation shortened stimulated seizures by 52% on average and reduced seizure incidence by 80.9% after 48 hours in 5 high-frequency therapy-resistant epilepsy patients. The signal is promising because it combines responsive seizure detection with electrode strips placed under the scalp rather than electrodes implanted …
A 2026 diagnostic-accuracy preprint found that resting-state EEG network features separated non-lesional epilepsy from functional/dissociative seizures (FDS) at 67.5% balanced accuracy, but the signal was not symmetrical: sensitivity was 81.8% for epilepsy and only 53.3% for FDS.1 In plain clinical terms, the model looked more useful as an epilepsy-supporting marker than as a positive test …
A 2026 CORE-VNS registry analysis found that implanted vagus nerve stimulation still produced large 36-month seizure reductions after failed intracranial epilepsy surgery: median all-seizure reduction was 76.3% with prior surgery vs. 76.6% without prior surgery.1 Research Highlights Prior surgery did not blunt the main VNS signal: CORE-VNS reported 76.3% median all-seizure reduction at 36 months …
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …
Epilepsy affects over 50 million people worldwide, making it one of the most common neurological disorders globally. For many living with epilepsy, achieving reliable seizure control remains a significant challenge, underscoring the need for continued innovation in treatment approaches. Exciting new developments in the field are providing clinicians with an expanding array of therapeutic options …